{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T07:36:45Z","timestamp":1791099405881,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ecl.2024.08.003","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T22:37:37Z","timestamp":1727390257000},"page":"513-523","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Latest on Anabolic Agents for Osteoporosis Treatment"],"prefix":"10.1016","volume":"53","author":[{"given":"Luigi","family":"di Filippo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford J.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ecl.2024.08.003_bib1","first-page":"785","article-title":"NIH consensus development panel on osteoporosis prevention, diagnosis, and therapy. Osteoporosis prevention, diagnosis, and therapy","volume":"285","year":"2001","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.ecl.2024.08.003_bib2","first-page":"2096","article-title":"Postmenopausal osteoporosis","volume":"374","author":"Black","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ecl.2024.08.003_bib3","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/nrrheum.2015.48","article-title":"A\u00a0look behind the scenes: the risk and pathogenesis of primary osteoporosis","volume":"11","author":"Hendrickx","year":"2015","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.ecl.2024.08.003_bib4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11657-017-0324-5","article-title":"UK clinical guideline for the prevention and treatment of osteoporosis","volume":"12","author":"Compston","year":"2017","journal-title":"Arch Osteoporosis"},{"issue":"4","key":"10.1016\/j.ecl.2024.08.003_bib5","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ecl.2018.07.003","article-title":"Physiology of parathyroid hormone","volume":"47","author":"Goltzman","year":"2018","journal-title":"Endocrinol Metab Clin N Am"},{"issue":"6","key":"10.1016\/j.ecl.2024.08.003_bib6","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1742-7843.2004.pto940602.x","article-title":"Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis","volume":"94","author":"Brixen","year":"2004","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"10.1016\/j.ecl.2024.08.003_bib7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1742-1241.2011.02837.x","article-title":"Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials","volume":"66","author":"Han","year":"2012","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ecl.2024.08.003_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2018.09.020","article-title":"Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: a systematic review and meta-analysis","volume":"120","author":"D\u00edez-P\u00e9rez","year":"2019","journal-title":"Bone"},{"issue":"10117","key":"10.1016\/j.ecl.2024.08.003_bib9","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ecl.2024.08.003_bib10","doi-asserted-by":"crossref","first-page":"101515","DOI":"10.1016\/j.beem.2021.101515","article-title":"Osteopathy in mild adrenal Cushing's syndrome and Cushing disease","volume":"35","author":"Frara","year":"2021","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"issue":"4","key":"10.1016\/j.ecl.2024.08.003_bib11","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s00774-017-0861-4","article-title":"Assessment of the effects of switching oral bisphosphonates to denosumab or daily teriparatide in patients with rheumatoid arthritis","volume":"36","author":"Ebina","year":"2018","journal-title":"J\u00a0Bone Miner Metabol"},{"issue":"4","key":"10.1016\/j.ecl.2024.08.003_bib12","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00198-011-1751-6","article-title":"The effects of combined human parathyroid hormone (1-34) and zoledronic acid treatment on fracture healing in osteoporotic rats","volume":"23","author":"Li","year":"2012","journal-title":"Osteoporos Int"},{"issue":"8","key":"10.1016\/j.ecl.2024.08.003_bib13","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s00198-021-05847-0","article-title":"Effectiveness of parathyroid hormone (PTH) analogues on fracture healing: a meta-analysis","volume":"32","author":"Eastman","year":"2021","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ecl.2024.08.003_bib14","doi-asserted-by":"crossref","first-page":"101117","DOI":"10.1016\/j.bonr.2021.101117","article-title":"The effect of osteoporosis and its treatment on fracture healing a systematic review of animal and clinical studies","volume":"15","author":"Gorter","year":"2021","journal-title":"Bone Rep"},{"issue":"11","key":"10.1016\/j.ecl.2024.08.003_bib15","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1007\/s00198-021-05996-2","article-title":"A\u00a0randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05","volume":"32","author":"Hagino","year":"2021","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.ecl.2024.08.003_bib16","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s00774-020-01171-5","article-title":"Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis: the TOWER-GO study","volume":"39","author":"Tanaka","year":"2021","journal-title":"J\u00a0Bone Miner Metabol"},{"issue":"4","key":"10.1016\/j.ecl.2024.08.003_bib17","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00198-020-05718-0","article-title":"Long-term cancer surveillance: results from the forteo patient registry surveillance study","volume":"32","author":"Gilsenan","year":"2021","journal-title":"Osteoporos Int"},{"issue":"2","key":"10.1016\/j.ecl.2024.08.003_bib18","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/jbmr.4188","article-title":"Teriparatide did not increase adult osteosarcoma incidence in a 15-year US postmarketing surveillance study","volume":"36","author":"Gilsenan","year":"2021","journal-title":"J\u00a0Bone Miner Res"},{"issue":"7","key":"10.1016\/j.ecl.2024.08.003_bib19","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1080\/14656566.2019.1583208","article-title":"Efficacy and safety of abaloparatide for the treatment of post-menopausal osteoporosis","volume":"20","author":"Merlotti","year":"2019","journal-title":"Expet Opin Pharmacother"},{"issue":"7","key":"10.1016\/j.ecl.2024.08.003_bib20","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [published correction appears in jama. 2017 Jan 24;317(4):442]","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2024.08.003_bib21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bone.2018.10.015","article-title":"Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: results from the ACTIVE phase 3 trial","volume":"120","author":"Miller","year":"2019","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.ecl.2024.08.003_bib22","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00198-020-05806-1","article-title":"Differential effects of abaloparatide and teriparatide on hip cortical volumetric BMD by DXA-based 3D modeling","volume":"32","author":"Winzenrieth","year":"2021","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.ecl.2024.08.003_bib23","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jocd.2021.11.007","article-title":"Abaloparatide effects on cortical volumetric BMD and estimated strength indices of hip subregions by 3D-DXA in women with postmenopausal osteoporosis","volume":"25","author":"Winzenrieth","year":"2022","journal-title":"J\u00a0Clin Densitom"},{"issue":"12","key":"10.1016\/j.ecl.2024.08.003_bib24","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1002\/jbmr.4719","article-title":"The efficacy and safety of abaloparatide-SC in men with osteoporosis: a randomized clinical trial","volume":"37","author":"Czerwinski","year":"2022","journal-title":"J\u00a0Bone Miner Res"},{"issue":"1","key":"10.1016\/j.ecl.2024.08.003_bib25","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s11657-023-01344-5","article-title":"The effects of abaloparatide on hip geometry and biomechanical properties in Japanese osteoporotic patients assessed using DXA-based hip structural analysis: results of the Japanese phase 3 ACTIVE-J trial","volume":"18","author":"Sone","year":"2023","journal-title":"Arch Osteoporosis"},{"issue":"1","key":"10.1016\/j.ecl.2024.08.003_bib26","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13018-023-03595-x","article-title":"Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis","volume":"18","author":"Hong","year":"2023","journal-title":"J\u00a0Orthop Surg Res"},{"issue":"1","key":"10.1016\/j.ecl.2024.08.003_bib27","doi-asserted-by":"crossref","first-page":"12258","DOI":"10.1038\/s41598-021-91729-8","article-title":"Short-term glucocorticoid excess blunts abaloparatide-induced increase in femoral bone mass and strength in mice","volume":"11","author":"Brent","year":"2021","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.ecl.2024.08.003_bib28","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1080\/17453674.2018.1523771","article-title":"Abaloparatide versus teriparatide: a head to head comparison of effects on fracture healing in mouse models","volume":"89","author":"Bernhardsson","year":"2018","journal-title":"Acta Orthop"},{"issue":"4","key":"10.1016\/j.ecl.2024.08.003_bib29","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/jor.24254","article-title":"Abaloparatide, a PTH receptor agonist with homology to PTHrP, enhances callus bridging and biomechanical properties in rats with femoral fracture","volume":"37","author":"Lanske","year":"2019","journal-title":"J\u00a0Orthop Res"},{"issue":"3","key":"10.1016\/j.ecl.2024.08.003_bib30","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40261-021-01008-7","article-title":"Phase 1b evaluation of abaloparatide solid microstructured transdermal System (Abaloparatide-sMTS) in postmenopausal women with low bone mineral density","volume":"41","author":"Miller","year":"2021","journal-title":"Clin Drug Invest"},{"issue":"10","key":"10.1016\/j.ecl.2024.08.003_bib31","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/jbmr.4877","article-title":"Efficacy and safety of transdermal abaloparatide in postmenopausal women with osteoporosis: a randomized study","volume":"38","author":"Lewiecki","year":"2023","journal-title":"J\u00a0Bone Miner Res"},{"issue":"11","key":"10.1016\/j.ecl.2024.08.003_bib32","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1210\/clinem\/dgaa450","article-title":"Cardiovascular safety of abaloparatide in postmenopausal women with osteoporosis: analysis from the ACTIVE phase 3 trial","volume":"105","author":"Cosman","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2024.08.003_bib33","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.3074","article-title":"WNT signaling in bone homeostasis and disease: from human mutations to treatments","volume":"19","author":"Baron","year":"2013","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.ecl.2024.08.003_bib34","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jbmr.3622","article-title":"One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study","volume":"34","author":"Lewiecki","year":"2019","journal-title":"J\u00a0Bone Miner Res"},{"issue":"9","key":"10.1016\/j.ecl.2024.08.003_bib35","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1210\/jc.2017-02163","article-title":"A\u00a0phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis","volume":"103","author":"Lewiecki","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2024.08.003_bib36","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.afos.2020.02.003","article-title":"Risk of falls in postmenopausal women treated with romosozumab: preliminary indices from a meta-analysis of randomized, controlled trials","volume":"6","author":"M\u00f6ckel","year":"2020","journal-title":"Osteoporos Sarcopenia"},{"issue":"1","key":"10.1016\/j.ecl.2024.08.003_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-021-06095-y","article-title":"A\u00a0systematic review and meta-analysis of efficacy and safety of Romosozumab in postmenopausal osteoporosis","volume":"33","author":"Singh","year":"2022","journal-title":"Osteoporos Int"},{"issue":"15","key":"10.1016\/j.ecl.2024.08.003_bib38","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.ecl.2024.08.003_bib39","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1111\/os.13136","article-title":"Romosozumab versus teriparatide for the treatment of postmenopausal osteoporosis: a systematic review and meta-analysis through a grade analysis of evidence","volume":"13","author":"Tian","year":"2021","journal-title":"Orthop Surg"},{"issue":"5","key":"10.1016\/j.ecl.2024.08.003_bib40","doi-asserted-by":"crossref","first-page":"e19595","DOI":"10.1371\/journal.pone.0019595","article-title":"The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells","volume":"6","author":"Zhu","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ecl.2024.08.003_bib41","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.atherosclerosis.2016.06.039","article-title":"Bisphosphonates for cardiovascular risk reduction: a systematic review and meta-analysis","volume":"252","author":"Kranenburg","year":"2016","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.ecl.2024.08.003_bib42","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1007\/s10067-020-04948-1","article-title":"Efficacy and safety of Romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis","volume":"39","author":"Kaveh","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ecl.2024.08.003_bib43","doi-asserted-by":"crossref","first-page":"115121","DOI":"10.1016\/j.bone.2019.115121","article-title":"Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: systematic review and meta- analysis","volume":"130","author":"Lv","year":"2020","journal-title":"Bone"},{"issue":"8","key":"10.1016\/j.ecl.2024.08.003_bib44","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2106\/JBJS.19.00790","article-title":"A\u00a0randomized, placebo-controlled study of romosozumab for the treatment of hip fractures","volume":"102","author":"Schemitsch","year":"2020","journal-title":"J\u00a0Bone Joint Surg Am"},{"issue":"16","key":"10.1016\/j.ecl.2024.08.003_bib45","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.2106\/JBJS.19.01008","article-title":"Romosozumab in skeletally mature adults with a fresh unilateral tibial diaphyseal fracture: a randomized phase-2 study","volume":"102","author":"Bhandari","year":"2020","journal-title":"J\u00a0Bone Joint Surg Am"},{"issue":"2","key":"10.1016\/j.ecl.2024.08.003_bib46","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/jbmr.2351","article-title":"A\u00a0randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density","volume":"30","author":"Recker","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"issue":"5","key":"10.1016\/j.ecl.2024.08.003_bib47","doi-asserted-by":"crossref","first-page":"724","DOI":"10.20945\/2359-3997000000564","article-title":"The why and how of sequential and combination therapy in osteoporosis. A review of the current evidence","volume":"66","author":"Chandran","year":"2022","journal-title":"Arch Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2024.08.003_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-019-05176-3","article-title":"Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures","volume":"31","author":"Kanis","year":"2020","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ecl.2024.08.003_bib49","doi-asserted-by":"crossref","first-page":"888208","DOI":"10.3389\/fphar.2022.888208","article-title":"Efficacy of the combination of teriparatide and denosumab in the treatment of postmenopausal osteoporosis: a meta-analysis","volume":"13","author":"Sun","year":"2022","journal-title":"Front Pharmacol"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852924000604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852924000604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T19:13:46Z","timestamp":1729624426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852924000604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0889852924000604"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2024.08.003","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Latest on Anabolic Agents for Osteoporosis Treatment","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2024.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}